je.st
news
Tag: merck
Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
2015-04-14 19:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & AMES, Iowa rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of Canadas National Microbiology Laboratory and licensed to NewLink Genetics in 2010. On Nov. Language: English Contact: Merck Media:Pam Eisele, 267-305-3558orImraan Munshi, 215-652-0059Investor:NewLink Genetics:Jack Henneman, 515-598-2561orMerck:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more
Merck releases new cattle handling video
2015-04-09 20:17:31| Beef
In an effort to help cattle producers better understand cattle behavior and become better and more efficient cattle handlers, Merck Animal Health launched its CreatingConnections website recently. Now, Merck has updated the site with an educational video about cattle shipping and transportation. read more
Tags: video
releases
handling
cattle
Merck releases new cattle handling video
2015-04-09 20:17:31| Beef
In an effort to help cattle producers better understand cattle behavior and become better and more efficient cattle handlers, Merck Animal Health launched its CreatingConnections website recently. Now, Merck has updated the site with an educational video about cattle shipping and transportation. read more
Tags: video
releases
handling
cattle
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
2015-04-06 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Company Receives EPA Honor for 10th Consecutive Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2015 Partner of the Year Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors. Language: English Contact: MerckMedia:Claire Gillespie, 267-305-0932orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: star
protection
energy
agency
Sites : [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] next »